BG64125B1 - Полиморфни форми на дофетилид - Google Patents

Полиморфни форми на дофетилид Download PDF

Info

Publication number: BG64125B1
Authority: BG; Bulgaria
Prior art keywords: dofetilide; polymorphic; preparation; treatment; pharmaceutically acceptable
Prior art date: 1997-10-27

Application number

BG104373A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104373A (en

Inventor

Ian C. Appleby

Trevor J. Newbury

Gary Nichols

Original Assignee

Pfizer Research And Development Company,N.V./S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-27

Filing date

2000-04-24

Publication date

2004-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10821150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64125(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-04-24 Application filed by Pfizer Research And Development Company,N.V./S.A. filed Critical Pfizer Research And Development Company,N.V./S.A.

2000-12-29 Publication of BG104373A publication Critical patent/BG104373A/xx

2004-01-30 Publication of BG64125B1 publication Critical patent/BG64125B1/bg

Links

IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 title claims abstract description 153
229960002994 dofetilide Drugs 0.000 title claims abstract description 152
239000000203 mixture Substances 0.000 claims abstract description 50
238000002360 preparation method Methods 0.000 claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 20
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 60
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
238000000634 powder X-ray diffraction Methods 0.000 claims description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
206010019280 Heart failures Diseases 0.000 claims description 14
238000000113 differential scanning calorimetry Methods 0.000 claims description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
238000002329 infrared spectrum Methods 0.000 claims description 10
238000010521 absorption reaction Methods 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 8
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
239000003416 antiarrhythmic agent Substances 0.000 claims description 7
229910052802 copper Inorganic materials 0.000 claims description 7
239000010949 copper Substances 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
206010003119 arrhythmia Diseases 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
-1 mixtures thereof Chemical compound 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
230000001747 exhibiting effect Effects 0.000 claims 2
239000000047 product Substances 0.000 description 29
239000000243 solution Substances 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
239000002245 particle Substances 0.000 description 19
150000001875 compounds Chemical class 0.000 description 14
238000001938 differential scanning calorimetry curve Methods 0.000 description 13
238000001914 filtration Methods 0.000 description 13
239000007787 solid Substances 0.000 description 13
238000002425 crystallisation Methods 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 11
230000008025 crystallization Effects 0.000 description 11
238000004566 IR spectroscopy Methods 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000000706 filtrate Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
230000000052 comparative effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000010992 reflux Methods 0.000 description 6
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 5
230000002861 ventricular Effects 0.000 description 5
230000036982 action potential Effects 0.000 description 4
ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 description 4
239000003610 charcoal Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000000227 grinding Methods 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000006793 arrhythmia Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
206010047281 Ventricular arrhythmia Diseases 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000003226 decolorizating effect Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
OBCFOPGCTNULTG-UHFFFAOYSA-N 1-(2-chloroethoxy)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OCCCl)C=C1 OBCFOPGCTNULTG-UHFFFAOYSA-N 0.000 description 1
BDCVRCLAXLOSLH-UHFFFAOYSA-N 115287-37-1 Chemical compound C=1C=C([N+]([O-])=O)C=CC=1CCN(C)CCOC1=CC=C([N+]([O-])=O)C=C1 BDCVRCLAXLOSLH-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
239000012267 brine Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000005611 electricity Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
VGJDSNZOPPZCTB-UHFFFAOYSA-N n-methyl-2-(4-nitrophenyl)ethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=C([N+]([O-])=O)C=C1 VGJDSNZOPPZCTB-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
210000003540 papillary muscle Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000002038 tachyarrhythmic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BG104373A 1997-10-27 2000-04-24 Полиморфни форми на дофетилид BG64125B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9722662.5A GB9722662D0 (en)	1997-10-27	1997-10-27	Polymorphs
PCT/EP1998/006641 WO1999021829A1 (en)	1997-10-27	1998-10-09	Dofetilide polymorphs

Publications (2)

Publication Number	Publication Date
BG104373A BG104373A (en)	2000-12-29
BG64125B1 true BG64125B1 (bg)	2004-01-30

Family

ID=10821150

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104373A BG64125B1 (bg)	1997-10-27	2000-04-24	Полиморфни форми на дофетилид

Country Status (46)

Country	Link
US (1)	US6124363A (es)
EP (1)	EP1027329B1 (es)
JP (1)	JP3569495B2 (es)
KR (1)	KR100366167B1 (es)
CN (1)	CN1146537C (es)
AP (1)	AP906A (es)
AR (1)	AR015193A1 (es)
AT (1)	ATE232199T1 (es)
AU (1)	AU737668B2 (es)
BG (1)	BG64125B1 (es)
BR (1)	BR9813308A (es)
CA (1)	CA2307121C (es)
CO (1)	CO4970768A1 (es)
DE (1)	DE69811256T2 (es)
DK (1)	DK1027329T3 (es)
DZ (1)	DZ2632A1 (es)
EA (1)	EA002656B1 (es)
ES (1)	ES2190620T3 (es)
GB (1)	GB9722662D0 (es)
GT (1)	GT199800165A (es)
HN (1)	HN1998000165A (es)
HR (1)	HRP20000247B1 (es)
HU (1)	HUP0004735A3 (es)
ID (1)	ID24658A (es)
IL (1)	IL135435A0 (es)
IS (1)	IS2179B (es)
MA (1)	MA24683A1 (es)
MY (1)	MY123352A (es)
NO (1)	NO325630B1 (es)
NZ (1)	NZ503785A (es)
OA (1)	OA11350A (es)
PA (1)	PA8462001A1 (es)
PE (1)	PE122199A1 (es)
PL (1)	PL197379B1 (es)
PT (1)	PT1027329E (es)
SA (1)	SA98190834B1 (es)
SI (1)	SI1027329T1 (es)
SK (1)	SK5862000A3 (es)
TN (1)	TNSN98193A1 (es)
TR (1)	TR200001135T2 (es)
TW (1)	TW449589B (es)
UA (1)	UA67755C2 (es)
UY (2)	UY25222A1 (es)
WO (1)	WO1999021829A1 (es)
YU (1)	YU24000A (es)
ZA (1)	ZA989719B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10019067C1 (de) *	2000-04-18	2001-10-04	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System zur Abgabe von Dofetilid und seine Verwendung
US7326772B2 (en) *	2005-05-12	2008-02-05	Penta Biotech, Inc.	Peptide for assaying hERG channel binding
CZ2017772A3 (cs)	2017-12-01	2019-05-29	Farmak, A.S.	Způsob přípravy N-[4-(2-{[2-(4-methansulfonamidofenoxy)ethyl](methyl)amino}ethyl)fenyl]methansulfonamidu (Dofetilidu)
US11344518B2 (en)	2018-08-14	2022-05-31	AltaThera Pharmaceuticals LLC	Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en)	2018-08-14	2023-07-11	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en)	2021-08-20	2025-08-26	AltaThera Pharmaceuticals LLC	Anti-arrhythmic compositions and methods
US10512620B1 (en)	2018-08-14	2019-12-24	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en)	2021-08-20	2023-03-21	AltaThera Pharmaceuticals LLC	Antiarrhythmic drug dosing methods, medical devices, and systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EG18188A (en) *	1986-05-01	1992-09-30	Pfizer Ltd	Process for preparation anti-arhythmia agents
EP0898964A1 (en) *	1997-08-19	1999-03-03	Pfizer Inc.	Method for treating heart failure

1997
- 1997-10-27 GB GBGB9722662.5A patent/GB9722662D0/en not_active Ceased
1998
- 1998-09-10 UA UA2000042087A patent/UA67755C2/uk unknown
- 1998-10-08 TW TW087116747A patent/TW449589B/zh not_active IP Right Cessation
- 1998-10-09 CN CNB988106213A patent/CN1146537C/zh not_active Expired - Fee Related
- 1998-10-09 EP EP98965638A patent/EP1027329B1/en not_active Expired - Lifetime
- 1998-10-09 PT PT98965638T patent/PT1027329E/pt unknown
- 1998-10-09 WO PCT/EP1998/006641 patent/WO1999021829A1/en not_active Ceased
- 1998-10-09 ES ES98965638T patent/ES2190620T3/es not_active Expired - Lifetime
- 1998-10-09 BR BR9813308-0A patent/BR9813308A/pt not_active Application Discontinuation
- 1998-10-09 US US09/423,986 patent/US6124363A/en not_active Expired - Lifetime
- 1998-10-09 EA EA200000365A patent/EA002656B1/ru not_active IP Right Cessation
- 1998-10-09 YU YU24000A patent/YU24000A/sh unknown
- 1998-10-09 AT AT98965638T patent/ATE232199T1/de not_active IP Right Cessation
- 1998-10-09 JP JP2000517941A patent/JP3569495B2/ja not_active Expired - Fee Related
- 1998-10-09 TR TR2000/01135T patent/TR200001135T2/xx unknown
- 1998-10-09 KR KR10-2000-7004471A patent/KR100366167B1/ko not_active Expired - Fee Related
- 1998-10-09 AU AU21512/99A patent/AU737668B2/en not_active Ceased
- 1998-10-09 DK DK98965638T patent/DK1027329T3/da active
- 1998-10-09 PL PL340805A patent/PL197379B1/pl unknown
- 1998-10-09 CA CA002307121A patent/CA2307121C/en not_active Expired - Fee Related
- 1998-10-09 HU HU0004735A patent/HUP0004735A3/hu unknown
- 1998-10-09 NZ NZ503785A patent/NZ503785A/en unknown
- 1998-10-09 HR HR970680A patent/HRP20000247B1/xx not_active IP Right Cessation
- 1998-10-09 IL IL13543598A patent/IL135435A0/xx not_active IP Right Cessation
- 1998-10-09 SI SI9830347T patent/SI1027329T1/xx unknown
- 1998-10-09 SK SK586-2000A patent/SK5862000A3/sk unknown
- 1998-10-09 DE DE69811256T patent/DE69811256T2/de not_active Expired - Fee Related
- 1998-10-09 ID IDW20000767A patent/ID24658A/id unknown
- 1998-10-22 PA PA19988462001A patent/PA8462001A1/es unknown
- 1998-10-22 AP APAP/P/1998/001371A patent/AP906A/en active
- 1998-10-23 AR ARP980105310A patent/AR015193A1/es unknown
- 1998-10-23 MY MYPI98004829A patent/MY123352A/en unknown
- 1998-10-23 PE PE1998001003A patent/PE122199A1/es not_active Application Discontinuation
- 1998-10-26 TN TNTNSN98193A patent/TNSN98193A1/fr unknown
- 1998-10-26 DZ DZ980242A patent/DZ2632A1/xx active
- 1998-10-26 UY UY25222A patent/UY25222A1/es not_active IP Right Cessation
- 1998-10-26 ZA ZA9809719A patent/ZA989719B/xx unknown
- 1998-10-26 HN HN1998000165A patent/HN1998000165A/es unknown
- 1998-10-26 MA MA25313A patent/MA24683A1/fr unknown
- 1998-10-27 CO CO98062885A patent/CO4970768A1/es unknown
- 1998-10-27 GT GT199800165A patent/GT199800165A/es unknown
- 1998-11-28 SA SA98190834A patent/SA98190834B1/ar unknown
1999
- 1999-01-08 UY UY25341A patent/UY25341A1/es not_active IP Right Cessation
2000
- 2000-03-31 IS IS5426A patent/IS2179B/is unknown
- 2000-04-20 OA OA1200000117A patent/OA11350A/en unknown
- 2000-04-24 BG BG104373A patent/BG64125B1/bg unknown
- 2000-04-27 NO NO20002191A patent/NO325630B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20002191L (no)	2000-04-27
ATE232199T1 (de)	2003-02-15
EP1027329A1 (en)	2000-08-16
CA2307121C (en)	2006-12-05
HUP0004735A2 (hu)	2001-10-28
ES2190620T3 (es)	2003-08-01
HRP20000247B1 (en)	2002-08-31
DE69811256T2 (de)	2003-09-18
BG104373A (en)	2000-12-29
CN1146537C (zh)	2004-04-21
WO1999021829A1 (en)	1999-05-06
NO20002191D0 (no)	2000-04-27
DZ2632A1 (fr)	2003-03-08
BR9813308A (pt)	2000-08-22
ZA989719B (en)	2000-04-26
PL197379B1 (pl)	2008-03-31
JP2001521023A (ja)	2001-11-06
AP906A (en)	2000-11-30
SI1027329T1 (en)	2003-04-30
GT199800165A (es)	2000-04-19
TNSN98193A1 (fr)	2005-03-15
CN1278246A (zh)	2000-12-27
HUP0004735A3 (en)	2001-12-28
UY25341A1 (es)	1999-09-27
MA24683A1 (fr)	1999-07-01
TR200001135T2 (tr)	2000-09-21
GB9722662D0 (en)	1997-12-24
OA11350A (en)	2003-12-17
US6124363A (en)	2000-09-26
EP1027329B1 (en)	2003-02-05
PT1027329E (pt)	2003-04-30
HK1033933A1 (en)	2001-10-05
PL340805A1 (en)	2001-02-26
PE122199A1 (es)	1999-12-02
AR015193A1 (es)	2001-04-18
HRP20000247A2 (en)	2000-10-31
ID24658A (id)	2000-07-27
AU2151299A (en)	1999-05-17
NZ503785A (en)	2004-11-26
IS5426A (is)	2000-03-31
IS2179B (is)	2006-12-15
YU24000A (sh)	2003-02-28
DK1027329T3 (da)	2003-02-24
UA67755C2 (uk)	2004-07-15
SA98190834B1 (ar)	2006-08-21
IL135435A0 (en)	2001-05-20
UY25222A1 (es)	2000-12-29
NO325630B1 (no)	2008-06-30
MY123352A (en)	2006-05-31
HN1998000165A (es)	1999-02-09
DE69811256D1 (de)	2003-03-13
SK5862000A3 (en)	2001-10-08
TW449589B (en)	2001-08-11
PA8462001A1 (es)	2000-05-24
KR20010031439A (ko)	2001-04-16
EA200000365A1 (ru)	2000-12-25
JP3569495B2 (ja)	2004-09-22
AP9801371A0 (en)	1998-12-31
CA2307121A1 (en)	1999-05-06
CO4970768A1 (es)	2000-11-07
AU737668B2 (en)	2001-08-30
KR100366167B1 (ko)	2003-01-09
EA002656B1 (ru)	2002-08-29

Publication	Publication Date	Title
MXPA04012923A (es)	2005-03-31	Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
KR20230021075A (ko)	2023-02-13	베타 아드레날린성 작용제의 형태 및 조성물
DE69332718T2 (de)	2003-12-04	Enantiomere von carbazolderivaten als 5-ht1-ähnliche agonisten
JP2023528565A (ja)	2023-07-05	Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
DE69112099T2 (de)	1996-02-08	Kristallinisches Salz von 4-(Di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indol.
TW202106680A (zh)	2021-02-16	Glyt1抑制劑之固體形式
BG64125B1 (bg)	2004-01-30	Полиморфни форми на дофетилид
EP3720435B1 (en)	2024-03-06	Crystal forms and production methods thereof
DE69815518T2 (de)	2004-04-22	S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
DE69324492T2 (de)	1999-09-02	1-azaadamantanderivate als 5-ht4 agonisten oder antagonisten und/oder 5-ht3 antagonisten
EP0254955A2 (de)	1988-02-03	Substituierte Pyrido-[2,3-b][1,4]benzodiazepin-6-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP5312022B2 (ja)	2013-10-09	Ｎｍｄａ受容体チャネルブロック作用を示す化合物及びそれを用いた薬剤。
EP0639568A1 (en)	1995-02-22	Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
CZ20001516A3 (cs)	2001-07-11	Polymorfy dofetilidu
US12215085B2 (en)	2025-02-04	Cholinesterase inhibitor polymorph and application thereof
PT1641797E (pt)	2007-12-21	Mesilato de hidrogénio de 4-(4-trans-hidroxicicloexil) amino-2-fenil-7h-pirroloii2,3d] pirimidina e suas formas polimórficas
CA2607257A1 (en)	2006-11-16	Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
HK40037540B (en)	2024-08-02	Crystal forms and production methods thereof
HK40037540A (en)	2021-06-11	Crystal forms and production methods thereof
DE102007032613A1 (de)	2008-01-24	Spiraprilhydrochlorid und polymorphe Formen davon
CA2456233A1 (en)	2003-03-13	Paroxetine isethionate salt, process of preparation and use in the treatment of depression
KR20050019792A (ko)	2005-03-03	카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는조성물, 및(또는) 치료 방법
HK1033933B (en)	2005-02-18	Dofetilide polymorphs